The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients

Media coverage

• Title	The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients
  Media name/outlet	BioSpace
  Country	United States
  Date	5/9/17
  Persons	Angela Alistar

• Title	The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
  Media name/outlet	4 Traders
  Country	United States
  Date	5/9/17
  Persons	Angela Alistar

• Title	The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
  Media name/outlet	PharmiWeb
  Country	United Kingdom
  Date	5/9/17
  Persons	Angela Alistar

• Title	The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
  Media name/outlet	GlobeNewswire
  Country	United States
  Date	5/9/17
  Persons	Angela Alistar

• Title	The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients
  Media name/outlet	Daily Times Leader
  Country	United States
  Date	5/9/17
  Persons	Angela Alistar

• Title	The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreatic Cancer
  Media name/outlet	PR Distribution
  Country	Poland
  Date	5/9/17
  Persons	Angela Alistar

• Title	The Lancet Oncology Publishes Phase I Data Demonstrating the Safety, Tolerability, and Preliminary Efficacy of Cornerstone Pharmaceuticals’ CPI-613 in Combination with Modified FOLFIRINOX in Patients with Metastatic Pancreati
  Media name/outlet	BizWire Express
  Country	India
  Date	5/9/17
  Persons	Angela Alistar